Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HBV vaccine + aqueous cream is a control intervention used in clinical research, specifically in trial NCT02621112. In this study, aqueous cream serves as a topical placebo pretreatment applied to the skin five minutes prior to the intramuscular injection of a hepatitis B virus (HBV) vaccine. The combination was designed to maintain blinding in studies evaluating the efficacy of topical immunomodulators, such as imiquimod, as adjuvants to improve the immunogenicity of HBV vaccination in populations with poor vaccine response, such as patients with end-stage renal disease on dialysis. The aqueous cream itself is an inert emollient with no active pharmaceutical ingredients, while the HBV vaccine is a standard prophylactic agent containing recombinant hepatitis B surface antigen (HBsAg).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HBV vaccine + aqueous cream.